Efficacy of ascites ultrafiltration concentration and peritoneal reinfusion in the treatment of refractory cirrhotic ascites in 305 cases

Abstract

Abstract: Objective To investigate the clinical efficacy of ascites ultrafiltration concentration and peritoneal reinfusion (referred to as ascites reinfusion) in the treatment for patients with refractory cirrhotic ascites.Methods A total of 305 patients with cirrhosis and refractory ascites admitted to our hospital from January 2019 to December 2020 were selected as the research objects. On the basis of conventional liver protection treatment and diuresis, ascites infusion therapy was performed. The clinical symptoms and signs (abdominal distention, anorexia, body weight, abdominal circumference, etc.) of the patients before and after treatment were observed. Laboratory indicators including serum creatinine (Scr), blood urea nitrogen (BUN), albumin, platelets, hemoglobin, and ascites routine were detected.Results After ascites reinfusion treatment, the clinical symptoms of 274 patients (89.8%) were improved, including weight loss, reduction in abdominal circumference, reduced bloating and dyspnea, and appetite improvement. Thirty-one patients (10.2%) had no obvious effect or progressed. During the treatment, 10 patients developed hypotension (3%), 4 patients muscle spasm (1.3%), and 2 patients mild abdominal pain (0.6%), all of which resolved spontaneously after operation and no serious complications occurred. After treatment, the Scr and BUN levels did not increase significantly, but the serum albumin level increased significantly (28.4 g/L vs. 29.6 g/L, P=0.000), and the platelet count decreased (93.34×10⁹ vs. 90.39×10⁹, P=0.006). There was no significant deference in serum sodium, international normalized ratio (INR), hemoglobin and other indicators before and after treatment.Conclusion Routine treatment combined with ascites reinfusion therapy can safely and effectively improve the clinical symptoms of patients with decompensated liver cirrhosis and refractory ascites.

Key words: Ascites reinfusion, Liver Cirrhosis, Refractory ascites, Treatment

TANG Ru-jia, ZHOU Xia, YAO Hong-yu, HU Yan-ming, WANG Huan, WANG Kai-li, XING Han-qian, ZHAO Jun, LIU Hong-ling. Efficacy of ascites ultrafiltration concentration and peritoneal reinfusion in the treatment of refractory cirrhotic ascites in 305 cases[J]. Chinese Hepatolgy, 2022, 27(12): 1268-1270.

References

[1] 中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南. 传染病信息, 2017, 30(5):1-17.
[2] 王淑珍,丁惠国.肝硬化顽固性腹水新的治疗模式及理念.中华肝脏病杂志, 2017, 25(4): 249-253.
[3] Runyon BA. AASLD practice guideline management of adult patients with ascites due to cirrhosis: Update 2012 . Hepatology, 2013, 2:1-27.
[4] Matsusaki K, Orihashi K. Feasibility, efficacy, and safety of cell-free and concentrated ascites reinfusion therapy (KM-CART) for malignant ascites. Artif Organs, 2020, 44 (10): 1090 - 1097.
[5] Neong SF, Adebayo D, Wong F. An update on the pathogenesis and clinical management of cirrhosis with refractory ascites. Expert Rev Gastroenterol Hepatol, 2019, 13(4): 293-305.
[6] Matsumoto N, Ogawa M, KandaT, et al. Largevolume cellfree and concentrated ascites reinfusion therapy improves venous fow in patients with liver cirrhosis.J Med Ultrason(2001), 2021, 48(3): 315-322.
[7] Yokomichi N, Imai K, Sakamoto M, et al. Feasibility of a fast-track randomized controlled trial of cell-free and concentrated ascites reinfusion therapy for patients with refractory malignant ascites. BMC Cancer, 2022, 22(1): 218.
[8] Nakamura H, Hanafusa N, Kitamura K, et al. Biochemical evaluation of processed ascites in patients undergoing cell-free and concentrated ascites reinfusion therapy.Ther Apher Dial, 2020, 24(5):516-523.
[9] 张鑫赫, 李异玲. 肝硬化顽固性腹水治疗现状. 实用肝脏病杂志, 2020, 23(05): 757-760.
[10] 成美娇, 郑伟强. 肝硬化顽固性腹水的治疗进展. 海南医学, 2019, 30( 2): 252-255.
[11] Hanada R, Yokomichi N, Kato C, et al. Efficacy and safety of reinfusion of concentrated ascitic fluid for malignant ascites: a concept-proof study.Support Care Cancer, 2018, 26(5):1489-1497.
[12] Koga K, Ishihara T, Doi Y, et al. Ultrastructural observation of filtration membrane in cell-free and concentrated ascites reinfusion therapy for malignant ascites. Ther Apher Dial, 2022, 26 (3): 649-657.
[13] Ohashi A, Nakai S, Hori H, et al. Suppression of inflammation during cell-free concentrated ascites reinfusion therapy using a blood purification device.Ther Apher Dial, 2020, 24 (5): 511 -515.
[14] Kozaki K, IInuma M, Takagi T, et al. Cell-free and concentrated ascites reinfusion therapy for decompensated liver cirrhosis. Ther Apher Dial, 2016, 20(4):376-82.
[15] Ito T, Hanafusa N, Soneda N, et al. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy against cirrhotic ascites in comparison with malignancy-related ascites. J Gastroenterol Hepatol, 2021, 36(11): 3224-3232.
[16] Fukui H, Kawaratani H, Kaji K, et al. Management of refractory cirrhotic ascites: challenges and solutions.Hepat Med, 2018, 3(10):55-71.
[17] Yasuda K,Asou M, Asakawa T, et al. Ascites management by cell-free concentrated ascites reinfusion therapy during recovery from drug-induced acute liver injury: a case report. J Med Case Rep, 2020, 14(1): 192.
[18] Lepida A, Marot A, Trepo E, et al. Systematic review with meta-analysis: automated low-flow ascites pump therapy for refractory ascites. Aliment Pharnacol Ther, 2019, 50(9): 978-987.
[19] Iwasa M, Ishihara T, Kato M, et al. Cell-free and concentrated ascites reinfusion therapy for refractory ascites in cirrhosis in post-marketing surveillance and the role of tolvaptan. Intern Med, 2019, 58(21):3069-3075.
[20] 杨蕊旭, 范建高. 欧洲失代偿期肝硬化并发症管理指南简介.实用肝脏病杂志, 2018, 21 (4): 496-501.